IL2RG and pancreatic neoplasm: To further evaluate the efficacy of these agents in pancreatic cancer, we utilized a primary patient derived xenograft model generated from a resected PDAC, and implanted tumors subcutaneously into the flanks of highly immunocompromised NOD/SCID/IL2rγ−/− mice.